Targeting Hypoxia in Advanced Prostate Cancer Using Tirapazamine-Copper Nanoparticles

Wafa Al-Jamal

University of East Anglia/ School of Pharmacy

Dr Wafa Al-Jamal completed her PhD in Drug Delivery in 2008 at UCL School of Pharmacy, London. She is currently a Prostate Cancer Research Fellow at The University of East Anglia (UEA). She joined UEA as a Lecturer in Drug Delivery in 2013, after working as a senior research fellow at University College London and King’s College London. Her research focuses on developing cancer nanomedicines for combinatory therapy and theranostic applications. Wafa was the GSK Emerging Scientist Award winner for 2015 for her research. Her multidisciplinary research has been funded by the Royal Society, Prostate Cancer UK and EPSRC.


Introduction: Hypoxia is considered a hallmark of cancer and a common characteristic of locally advanced solid cancers, including prostate cancer. Tumor hypoxia plays a key role in promoting angiogenesis, metastasis, and drug... [ view full abstract ]


  1. Wafa Al-Jamal (University of East Anglia/ School of Pharmacy)
  2. Vera Silva (University of East Anglia/ School of Pharmacy)

Topic Areas

Targeted drug delivery and Nanocarriers , Nanomedecine for cancer diagnosis & therapy


OS3-103 » Nanomedecine for cancer diagnosis & therapy (16:00 - Friday, 30th September, Tower 24 - Room 103)

Presentation Files

The presenter has not uploaded any presentation files.